<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00843661</url>
  </required_header>
  <id_info>
    <org_study_id>EFP01</org_study_id>
    <nct_id>NCT00843661</nct_id>
  </id_info>
  <brief_title>Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients</brief_title>
  <official_title>Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients Receiving Protease Inhibitors: a Randomized, Prospective, Controlled Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale di Circolo - Fondazione Macchi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ospedale di Circolo - Fondazione Macchi</source>
  <brief_summary>
    <textblock>
      -  The aim of the study is to compare the effects of coadministration of ezetimibe 10&#xD;
           mg/die + fenofibrate 200 mg/die versus pravastatin 40 mg/die monotherapy in HIV-infected&#xD;
           patients treated with protease inhibitors.&#xD;
&#xD;
        -  Single-centre, open, randomized, controlled, prospective pilot study.&#xD;
&#xD;
        -  60 patients will be enrolled in order to reach the target of 50 patients evaluable at&#xD;
           the end of the study. The patients will be randomly assigned to a 6-month treatment with&#xD;
           ezetimibe+fenofibrate or with pravastatin.The visit will be every month.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>per cent changes of LDL cholesterol, comparison between the 2 treatment regimens</measure>
    <time_frame>After 6 month treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HIV</condition>
  <condition>Hyperlipidemia</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Ezetimibe and fenofibrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pravastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe</intervention_name>
    <description>10 mg ezetimibe/day</description>
    <arm_group_label>Ezetimibe and fenofibrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fenofibrate</intervention_name>
    <description>200 mg fenofibrate/day</description>
    <arm_group_label>Ezetimibe and fenofibrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pravastatin</intervention_name>
    <description>40 mg pravastatin/day</description>
    <arm_group_label>Pravastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients older than 18 years&#xD;
&#xD;
          -  documented positive HIV antibodies test&#xD;
&#xD;
          -  on stable therapy with PIs for at least 12 months&#xD;
&#xD;
          -  LDL-cholesterol &gt;130 mg/dl or triglycerides 200 - 500 mg/dl with non-HDL cholesterol&#xD;
             &gt;160 mg/dl&#xD;
&#xD;
          -  unresponsive to dietary measures and regular physical exercise of at&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of dyslipidemia before antiretroviral therapy&#xD;
&#xD;
          -  cardiovascular and cerebrovascular diseases&#xD;
&#xD;
          -  Cushing's syndrome&#xD;
&#xD;
          -  concurrent therapy with lipid-lowering agents, oral anticoagulant, estrogens,&#xD;
             thiazidic diuretics, beta-blockers&#xD;
&#xD;
          -  hypothyroidism&#xD;
&#xD;
          -  Type 1 diabetes mellitus&#xD;
&#xD;
          -  renal failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna Maria Grandi, MD</last_name>
    <phone>+390332278403</phone>
    <email>amgrandi@libero.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ospedale di Circolo and Fondazione Macchi</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Maria Grandi, MD</last_name>
      <phone>+390332278403</phone>
      <email>amgrandi@libero.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>February 12, 2009</study_first_submitted>
  <study_first_submitted_qc>February 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2009</study_first_posted>
  <last_update_submitted>August 1, 2011</last_update_submitted>
  <last_update_submitted_qc>August 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Anna Maria Grandi</name_title>
    <organization>Ospedale di Circolo Fondazione MAcchi</organization>
  </responsible_party>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

